InflaRx Stock Discussion

$InflaRx (IFRX.US)$ InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
1 MINUTE AGO, 7:51 AM EST
VIA GLOBENEWSWIRE

$InflaRx (IFRX.US)$
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
InflaRx presented a post hoc analysis of the SHINE Phase 2b study of vilobelimabin hidradenitis suppurativa (HS) at the 2024 EADV Congress. The analysis focused on the 1200 mg dose, which showed significant improvements compared to placebo at 16 weeks:
- 45.2% reduction in draining tunnels
- 25.1% reduction in tot...

$InflaRx (IFRX.US)$
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, will present preclinical data on INF904, their novel oral C5aR inhibitor, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) in Lübeck, Germany, from September 2-6, 2024. The company will showcase two poster presentations, participate in a C5a/C...

$InflaRx (IFRX.US)$
NEWS
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

$InflaRx (IFRX.US)$ getting interesting phase 1 went good